or Try an Advanced Search...

    Technical Analysis for XLO - Xilio Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 1.21 -3.97% -0.05
    XLO closed down 3.97 percent on Wednesday, May 8, 2024, on 11 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical XLO trend table...
    Date Alert Name Type % Chg
    MACD Bullish Signal Line Cross Bullish 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Earnings Movers Other 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Shooting Star Candlestick Bearish -3.97%
    Lizard Bearish Bearish Day Trade Setup -3.97%
    NR7 Range Contraction -3.97%
    Narrow Range Bar Range Contraction -3.97%
    Doji - Bearish? Reversal -3.97%
    Older End-of-Day Signals for XLO ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support about 12 hours ago
    Down 5% about 15 hours ago
    Down 3% about 15 hours ago
    Down 2 % about 15 hours ago
    Lizard Bearish Entry about 16 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    XLO Chart by TradingView
    Basic chart:

    Profile

    Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Tumor Cancer Immunotherapy Immunotherapies Immune Checkpoint Checkpoint Inhibitor Tumor Microenvironment

    Is XLO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 16 Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
    Apr 1 Xilio Therapeutics reports Q4 results
    Apr 1 Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
    Apr 1 Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
    Mar 28 Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results
    Mar 28 Xilio stock jumps on Gilead Sciences license deal
    Mar 28 Xilio Therapeutics announces $11.3 million private placement equity financing
    Mar 28 Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
    Mar 28 Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
    Mar 28 Gilead bets on Xilio cancer drug as biotech restructures
    See more XLO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.25
    52 Week Low 0.49
    Average Volume 1,478,130
    200-Day Moving Average 1.46
    50-Day Moving Average 1.00
    20-Day Moving Average 1.16
    10-Day Moving Average 1.12
    Average True Range 0.14
    RSI (14) 55.56
    ADX 28.75
    +DI 25.18
    -DI 16.04
    Chandelier Exit (Long, 3 ATRs) 1.08
    Chandelier Exit (Short, 3 ATRs) 1.36
    Upper Bollinger Bands 1.36
    Lower Bollinger Band 0.95
    Percent B (%b) 0.62
    BandWidth 35.43
    MACD Line 0.04
    MACD Signal Line 0.04
    MACD Histogram 0.0009
    Fundamentals Value
    Market Cap 33.31 Million
    Num Shares 27.5 Million
    EPS -2.96
    Price-to-Earnings (P/E) Ratio -0.41
    Price-to-Sales 0.00
    Price-to-Book 0.31
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.41
    Resistance 3 (R3) 1.41 1.35 1.37
    Resistance 2 (R2) 1.35 1.30 1.35 1.36
    Resistance 1 (R1) 1.28 1.27 1.25 1.28 1.35
    Pivot Point 1.22 1.22 1.21 1.22 1.22
    Support 1 (S1) 1.15 1.17 1.12 1.15 1.07
    Support 2 (S2) 1.09 1.14 1.09 1.06
    Support 3 (S3) 1.02 1.09 1.05
    Support 4 (S4) 1.02